Clinical and Translational Research Infrastructure Network (CTR-IN) and Western Region IDeA Networks for Biomedical Research Excellence (INBRE) Programs
Funding Opportunity Announcement (FOA): Developmental Translational Team Grant (DTTG)

Overview: The Mountain West Clinical Translational Research Infrastructure Network (CTR-IN) is supported by the National Institute of General Medical Sciences (NIGMS) under the Institutional Development Award (IDeA) program for development of clinical and translational research (CTR) capacity among our partner Mountain West IDeA states. The West Region INBRE programs are funded by NIGMS IDeA with the goal of building biomedical education and research infrastructure in their states. A long-term goal for MW CTR-IN and INBRE programs is to partner across IDeA programs in the region to enhance collaboration between clinical, preclinical and basic science investigators and their access to resources in support of biomedical research. The long-term goal of this program is to build extramurally-funded collaborative CTR-INBRE projects engaging clinical, pre-clinical and basic science researchers in Mountain West States to address critical regional health disparities issues. The purpose of this FOA is to provide support for a clinical investigator teamed with a basic science or a pre-clinical investigator to yield a project “proof-of-concept” for a subsequent, larger extramural (NIH, NSF, DoD, USDA, etc.) grant application. Moreover, the proposals should include how this funding will facilitate the team’s specific plan to apply for additional funding.

Eligibility to lead Developmental Team Training Project:
- A successful proposal will describe a CTR project co-directed by a clinical investigator collaborating with a basic science or preclinical investigator both with faculty appointments at Mountain West CTR-IN institutions in the same IDeA state.
- The Investigators may not concurrently serve as a Principal Investigator (PI) on an IDeA award from another IDeA program (i.e., CTR, COBRE or INBRE).

Funding Source: National Institute of General Medical Sciences (NIGMS U54GM104944 and P20GM103432)

Key Dates:

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Request for Proposals Published</td>
<td>23 October, 2020</td>
</tr>
<tr>
<td>Applications Due to Wyoming INBRE</td>
<td>05 February, 2021</td>
</tr>
<tr>
<td>Award(s) announced</td>
<td>05 March, 2021</td>
</tr>
<tr>
<td>Earliest start date.</td>
<td>01 September, 2021 (pending NIGMS approval)</td>
</tr>
<tr>
<td>Project end date (or 6 months following start date)</td>
<td>01 February, 2021</td>
</tr>
</tbody>
</table>

Project Duration: Six months. No carryover beyond project period. All funds must be encumbered at the latest by April 30, 2021.

Process:
Applications submitted to the INBRE Director will include:
  o a face page (fp2),
- project summary,
- 2-page research strategy/concept paper,
- NIH biosketch for team members,
- budget and budget justification,
- a letter from the INBRE Director stating support for the preclinical/basic science half of the team,
- * See below- completed Human Subjects Form F, a copy of the IRB approval, and investigator CITI certificates.

The budget should be prepared as two separate documents with one budget identified for the CTR-IN-supported portion (i.e., clinical investigator) and one budget identified for the INBRE-supported portion (basic scientist or pre-clinical investigator) [see Overall Budget below].

This mechanism is not intended to fund new human subjects research. However, if planned preliminary data involves human subjects it should be based on data captured under a previously IRB-approved protocol (or exempt). For example, this mechanism will not support new collection of biological samples from human subjects, but it can support new analyses of biological samples that were previously collected provided that the new analysis was already approved under the existing IRB protocol.

*If the proposed study involves new analyses of human subjects biological samples that were previously collected and the new analysis is approved under an existing IRB protocol, you must also submit a completed Human Subjects Form F, a copy of the IRB approval, and investigator CITI certificates. For additional guidance see https://www.nidcd.nih.gov/research/clinical-studies/researchers-professionals/human-subjects-clinical-trials-information-form.

**Funding level and allowable expenses:**
Total costs of up to $20,000 direct costs may be requested. Funds can be used for supplies, equipment, or travel for team or community meetings. Funds are intended to be for team building, hypothesis generation, and capture of preliminary data. If planned preliminary data involves human subjects it should be based on data captured under a previously IRB-approved protocol (or exempt). For example, this mechanism will not support new collection of biological samples from human subjects, but it can support new analyses of biological samples that were previously collected provided that the new analysis was already approved under the existing IRB protocol.

All expenses must be allowable under NIH guidelines. Additionally, the following restrictions apply:
- Equipment costs over $5,000 – not allowable.
- Significant foreign participation – not allowable.
- Laptops/computers – not allowable.
- Tuition and fees for graduate students – not allowable. However, salary support is allowable.
• Subcontracts to institutions located in non-IDeA states – not allowable. However, services provided in non-IDeA states can be purchased on a fee-for-service basis.
• Publication costs (i.e., page charges) – not allowable.

**Overall budget:**
We anticipate funding up to seven projects (1 per Western IDeA state) under this announcement pending NIGMS approval. For each award CTR-IN will allocate up to $10K to support the clinical investigator half of the preclinical or clinical team, and the corresponding state INBRE program will support the basic science research investigator half of the team up to $10K.

**If you have questions contact:**
R. Scott Seville, Ph.D.
Professor and Chair, Department of Zoology and Physiology, [http://www.uwyo.edu/zoology/](http://www.uwyo.edu/zoology/)
Director, NIH IDeA Wyoming INBRE, [www.uwyo.edu/wyominginbre](http://www.uwyo.edu/wyominginbre)
Assoc. Director, NIH IDeA Mountain West CTR-IN Pilot Grant Program, [https://ctrin.unlv.edu/](https://ctrin.unlv.edu/)
University of Wyoming- Laramie, 1000 E. University, BS 428B and HH 234, Laramie, WY 82071
University of Wyoming- Casper, 125 College Drive, UU 438, Casper, WY 82601
sseville@uwyo.edu

Or
MW CTR-IN Pilot Grant Program
Dr. Curtis Noonan ([curtis.noonan@mso.umt.edu](mailto:curtis.noonan@mso.umt.edu)) and Dr. Scott Seville ([sseville@uwyo.edu](mailto:sseville@uwyo.edu))

**CTR-IN Institutions:**
- Boise State University
- Idaho State University
- Montana State University
- New Mexico State University
- University of Alaska, Anchorage
- University of Alaska, Fairbanks
- University of Hawaii
- University of Idaho
- University of Montana
- University of Nevada Las Vegas
- University of Nevada Reno
- University of Wyoming
- University of New Mexico